Intranasal Phototherapy Is More Effective Than Fexofenadine Hydrochloride in the Treatment of Seasonal Allergic Rhinitis: Results of a Pilot Study

We recently showed that intranasal phototherapy represents an efficient therapeutic modality for the treatment of patients with seasonal allergic rhinitis (SAR). The aim of this pilot study was to compare the efficacy of intranasal phototherapy with that of the new generation antihistamine fexofenad...

Full description

Saved in:
Bibliographic Details
Published in:Photochemistry and photobiology 2011-03, Vol.87 (2), p.474-477
Main Authors: Garaczi, Edina, Boros-Gyevi, Márta, Bella, Zsolt, Csoma, Zsanett, Kemény, Lajos, Koreck, Andrea
Format: Article
Language:English
Subjects:
Administration, Intranasal
Adolescent
Adult
Allergies
Ambrosia - immunology
Anti-Allergic Agents - administration & dosage
Anti-Allergic Agents - therapeutic use
Drug therapy
Female
Humans
Light therapy
Male
Middle Aged
Phototherapy - standards
Pilot Projects
Rhinitis, Allergic, Seasonal - drug therapy
Studies
Terfenadine - administration & dosage
Terfenadine - analogs & derivatives
Terfenadine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We recently showed that intranasal phototherapy represents an efficient therapeutic modality for the treatment of patients with seasonal allergic rhinitis (SAR). The aim of this pilot study was to compare the efficacy of intranasal phototherapy with that of the new generation antihistamine fexofenadine HCl in SAR. A randomized open study was conducted in patients with a history of moderate‐to‐severe ragweed‐induced SAR. Thirty‐one patients were randomly assigned to receive either intranasal irradiation three times a week for 2 weeks, or 180 mg fexofenadine HCl per day for 2 weeks. Each patient kept a diary of symptoms for nasal obstruction, nasal itching, rhinorrhea, sneezing and palate itching. Total nasal score (TNS), a sum of scores for nasal symptoms, was also calculated. In the rhinophototherapy group the individual scores significantly decreased compared with baseline for all of the parameters. In the fexofenadine HCl group none of the scores improved significantly at the end of the treatment except sneezing. TNS was significantly decreased in the rhinophototherapy group, but no significant change was observed in the fexofenadine HCl group after 2 weeks of treatment. In conclusion, we found that intranasal phototherapy is more efficient than fexofenadine HCl in reducing clinical symptoms for SAR.
ISSN:0031-8655
1751-1097
DOI:10.1111/j.1751-1097.2010.00882.x